The FemTech Capital Pivot: Bridging the Funding Gap through Evidence Maturity
Despite representing a multi-billion euro opportunity, FemTech continues to face a disproportionate funding gap. At the MTI25 Helsinki Summit, we aren’t just discussing the problem—we are pivoting the strategy.
The FemTech Investor Roundtable: Where the future of women’s health innovation meets the decision-makers with the power to transform it. Hosted by inXso, this selective gathering aims to accelerate significant medical advancements for underserved communities by connecting leading women’s health innovators with key institutional investors.
Who is it for?
1. The Innovators
FemTech startups and scale-ups, including EIC Pathfinder, Transition, and Accelerator beneficiaries, who are ready to move beyond laboratory proof to market-ready substance:
– Proven Technologies
– Clear Regulatory Roadmap
– Women-First Focus
If you are developing life science tools, diagnostics, or digital health solutions specifically for women’s health, this table is for you.
2. The Investors
Specialised FemTech funds, generalist VCs looking to diversify into high-growth sectors, and institutional investors who demand “Evidence Maturity” before committing Series A or B capital.
3. The Policymakers
Strategic stakeholders are interested in how harmonised regulations (like the 2026 FDA/EUDAMED transitions) can be used as a lever to de-risk women’s health investments.
Why Participate?
For Innovators: Precision Matchmaking & Stress-Testing
Traditional pitching often fails to address the specific ‘due diligence’ hurdles unique to FemTech. At this roundtable, you don’t just pitch; you engage in a Strategic Stress-Test. This exercise provides founders with a comprehensive readiness score, a tailored roadmap for growth, and a readiness tier classification that highlights their current position in the investment landscape. This explicit outcome ensures that participants walk away with actionable insights for immediate application and strategic advancement.
- Gain Strategic Clarity: Understand how to leverage your regulatory trajectory to justify a higher pre-money valuation (up to 25% premium).
- Direct Access: Engage in precision matchmaking with specialised Women Investors and VCs who understand the FemTech monetisation arc.
- The Pioneer Award: Participation puts you in the running for the MTI25 Women’s Health Pioneer Award, which includes a €5,000 Regulatory Strategy Grant to help close your evidence gaps.
For Investors: De-Risked Deal Flow
The biggest barrier to FemTech investment is often a lack of auditable technical substance.
- Vetted Ventures: Meet founders who have undergone the inXso Investor Readiness Scorecard (IRSc) diagnostic.
- Evidence Maturity: Review ventures that are proactively aligning with 2026 mandates (FDA QMSR/EUDAMED), ensuring a swifter, smoother due diligence process.
- First-Look Advantage: Gain early access to the top-performing EIC-funded FemTech projects in Europe.
What You Will Gain
The “Capital Pivot” roundtable is structured to move participants from dialogue to deal-making:
- The Diagnostic Map: A clear understanding of the “Evidence Maturity” required to close a Series A in 2026.
- Regulatory Leverage: Insights into how the new EU HTAR regulations impact FemTech valuations.
- Funding Strategy: Access to the inXso Funding Strategy framework to ensure your “Path to Payment” logic is bulletproof.
A Call to Action for Women’s Health Pioneers
Eligibility · Who can participate?
The historical under-investment in FemTech is a market inefficiency we are here to correct. By participating in this roundtable, you are not just attending a session; you are joining a collaborative movement to ensure that women’s health innovation receives the institutional capital it deserves. Together, we can transform ideas into impact, one pioneering effort at a time.
- Date: 16 March 2026
- Location: MTI25 Summit, Helsinki
- Provider: inXso (via the EIC ACCESS+ initiative)
